Bevacizumab Biosimilar

About Dr. Reddy's Laboratories

Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.

About Bio Usawa Biotechnology

African biotech building low‑cost monoclonal antibody biosimilars to expand cancer treatment access.

About Laboratorio Elea Phoenix

Argentina‑based pharma firm providing a wide range of generic APIs and finished products for global markets.

About Biomm

Brazil’s leading biotech producing insulin and biosimilar biologics for oncology and ophthalmology.

About Cipla

Cipla's mission is to ensure that no patient is denied access to high-quality, affordable medicine. A global leader with a market valuation exceeding $988 billion, the company has achieved this through pioneering complex generics, strategic international expansion, and a robust manufacturing footprint. Its core strategy leverages deep R&D in respiratory and oncology, vertical integration via API production, and a diversified geographic presence to drive sustainable growth and market leadership.

About Sandoz Group

Sandoz is a mission-driven global leader in generics and biosimilars, focused on expanding sustainable access to medicines. Its strategic independence, following the 2023 spin-off, allows for dedicated capital allocation and agile execution in a market driven by patent expiries and cost containment. The company's dual-pillar strategy encompasses a deep pipeline of complex generics and a leading portfolio of biosimilars, supported by world-class development and manufacturing capabilities. With a commercial reach serving approximately 500 million patients annually, Sandoz is positioned to capitalize on significant market opportunities while delivering on its purpose.

About dr-reddys-laboratories

Founded in 1984, Dr. Reddy's has evolved from an API manufacturer into a fully integrated global pharmaceutical enterprise with a mission to provide affordable and innovative medicines. Its strategy is built on a four-pillar business model—Generics, API & Services, Innovative Medicines, and Consumer Health—leveraging deep scientific capabilities in complex generics, biosimilars, and novel drug discovery. Recent milestones, including the launch of India's first generic semaglutide and key biosimilar approvals in major markets, underscore its growth trajectory and commitment to addressing unmet patient needs globally.

Therapeutic Areas

Other Various Cancers Drugs